MRNA Moderna
too hard · 24
Owner-earnings value—
Price$194.82
Margin of safety
—
Quality gate · 24/100
⚠ sub-hurdle returns (median roic -24% < 9%) · unprofitable in too many years
Median ROIC-23.9%
Gross margin22.8%
Share count / yr+0.8%
Profitable years1/4
Moat & management
Owner-earnings inputs
| Owner earnings (TTM) | -3.08B |
| Owner-earnings yield | -4.0% |
| Free-cash-flow yield | -1.6% |
| Growth used (normalized) | — |
| Terminal growth | — |
| Discount rate (hurdle) | — |
Recent news
score · 8 articles
- Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.
- MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
- Moderna Inc. (MRNA) Holds High-Level Investment Talks With UAE, Soars to 4-Year Peak
- From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done
- Moderna's View of the Global Pharma Industry
- Why Did META, MRNA, OKTA Stocks Surge To 52-Week Highs Today?
- Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
- These 2 Stocks Are Bucking The Broader Market Selloff To Hit New Multi-Year Highs — Here’s What’s Driving The Enthusiasm
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · non-positive owner earnings — cannot value as a going wonderful business